Chiltern, Charles River Labs Partner on Early-phase Studies

Friday, February 26, 2010 06:54 AM

UK contract research organization (CRO) Chiltern International and preclinical CRO Charles River Laboratories are partnering to conduct and support early-phase radiolabelled studies.

The two companies will collaborate on studies using radiolabelled investigational products out of the CROs’ Europe-based facilities.

Chiltern’s early stage division—Chiltern Early Phase—in Dundee, Scotland, will perform the clinical aspects of the studies. The CRO has a 42-bed clinical pharmacology unit located in a UK National Health Service hospital and medical school. Charles River’s Metabolism and Pharmacokinetics facilty in Edinburgh includes a GMP clean room, licensed for the manufacture of radiolabelled drug products. The close proximity of the two laboratories enables the companies to turn around radioactivity data within 24 hours.

“This new partnership is an exciting collaboration. Charles River’s reputation is world-renowned for their conduct of studies using radiolabelled investigational products. Their extensive experience includes submission and review procedures for radiolabelled studies in man, including dosimetry calculations and submission to ARSAC,” said Chiltern CEO Glenn Kerkhof in a statement. “These complementary strengths add a new dimension to the full CRO services that Chiltern already provides, continuing to demonstrate our commitment to providing our clients with the highest standard of quality and expertise.”

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs